Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma
Just a decade ago, immune therapy for multiple myeloma barely existed as an idea. Since then, immune therapy has evolved rapidly and the field is on the verge of major improvements in outcomes.
Zelenoleucel in Phase 2 Study of Patients With AML
The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.
Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for ...
Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.
Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADC...
High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.
How do I manage the risk of infection in patients treated with immunotherapies?
During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage the risk of infection in patients treated with immunotherapies?
Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma
Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immun...
T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.
Cancer Immunotherapy: 2021 Research and Look Ahead - Webinar for patrients and c...
CRI Scientific Advisory Council Associate Director Dr. Kunle Odunsi discusses the future of cancer immunotherapy and what may lie ahead for the field.